Pharma BD Deal Intelligence
Pfizer will pay $1.25 billion upfront and up to $6.05 billion in total to license 3SBio's SSGJ-707, a PD-1/VEGF bispecific antibody currently in Phase…
With Summit leading the pack in PD-1xVEGF bispecifics, Pfizer lays out its own plan to replace Keytruda with the 3SBio asset. The article frames the deal as…
Pfizer ASCO 2026: updated Phase 2 data for PF-08634404 (SSGJ-707), the PD-1/VEGF bispecific, as monotherapy in first-line PD-L1-expressing NSCLC (Abstract…
Source summaries from our enrichment pipeline; follow links for originals.
All 17 sources with sentiment breakdown →
Pfizer licensed SSGJ-707 (PF-08634404), a PD-1/VEGF bispecific antibody, from 3SBio, paying $1.25B upfront plus a $100M equity investment in a deal worth up to $6.05B (including up to $4.8B in milestones) for global rights ex-China in lung, colorectal and gynecologic cancers. The deal closed July 24, 2025. As of ASCO 2026, Pfizer is advancing the asset in pivotal development -- the Phase 3 Symbiotic-Lung-01 study in first-line NSCLC (plus chemotherapy, regardless of PD-L1 status) and the Phase 3 Symbiotic-GI-03 study in first-line metastatic colorectal cancer -- alongside updated Phase 2 first-line NSCLC monotherapy data.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / 3SBio Inc. (this deal) | 2025 | $6.0B | 62 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2025 deals · Pfizer Inc. deals · Oncology deals